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Introduction
               Atrial fibrillation (AF) is the most frequent sustained cardiac arrhythmia in clinical
practice and, although its importance has been underestimated even in recent years, we are now
becoming aware of its clinical transcendence1,2,3. The classical treatment is pharmacological, but
its efficacy is limited and it does have side effects4,5. Therefore, in recent years, there has been an
increasing interest in other types of non-pharmacological treatments6,7.
            Physiologic cardiac pacing has proven to be more effective than VVI mode pacing to
prevent the occurrence of AF during the follow-up of patients who have had a permanent
pacemaker implanted 8,9,10. There are currently different lines of research that use different atrial
pacing techniques to prevent and treat episodes of paroxysmal atrial fibrillation11,12. Techniques
of multi-site pacing in the right atrium or both atria, new atrial pacing sites, prevention
algorithms   for   paroxysmal   atrial   fibrillation   episodes,   and   even   high-frequency   atrial
tachyarrhythmia termination algorithms have all been proposed. In this article, we will try to
synthesize the grounds for and findings of the different lines of research currently being
developed. 
Pacing Activation Mechanisms
              The occurrence of atrial fibrillation in a patient depends on the interaction of three
factors:   substratum,   triggers  and  modulating  factors.   The substratum   is   the   usually  sick
atrial myocardium with areas of fibrosis that result in heterogeneous refractoriness that facilitates
the appearance of functional reentry areas. Shortening the refractory periods that take place in
atrial myocardium as a result of electrical remodeling favors the perpetuation of AF13. The
triggers are the atrial extra-systoles or episodes of atrial tachycardia or flutter that in many cases
precede episodes of AF14. The modulating factors such as sympathicotonia or circulating
catecholamines facilitate the occurrence and sustainability of AF.
    Atrial pacing can prevent the development of AF through several mechanisms. It can prevent
dispersion of the atrial refractory periods associated with bradycardia. This effect can be
particularly beneficial in cases of vagotonic AF15,16. New approaches of interatrial septal,
Bachmann or simultaneous dual-site pacing have demonstrated an enhanced speed of conduction
of the electric pulse through the atrium. This higher speed of conduction is reflected in a shorter
duration of the P wave of the superficial electrocardiogram17,18,19 and can help to prevent AF.
    Atrial pacing at frequencies higher than the basal frequency can prevent the occurrence of AE
by overdrive suppression, or at least significantly decrease their number. It can also decrease the
post-AE pauses that result in high dispersion in the refractory periods. In addition, it can suppress
the increased automatism that is responsible for focal AF20.
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    The new techniques of multi-site pacing can improve the hemodynamics of sick atria, and this
hemodynamic improvement can in itself prevent episodes of  AF21. Finally, the episodes of high-
frequency atrial tachycardia that often precede the occurrence of AF can, on occasions, be
terminated with atrial pacing22.
Patients with Permanent Pacing Indication
            In 1994, Andersen and Cols23 published the results of the first randomized trial that
compared physiologic pacing with VVI mode. It included 225 patients with sinus node
dysfunction and narrow QRS and an average age of 76 years who were randomized to receive an
AAI versus VVI pacemaker. The long-term follow-up of these patients was published in 19978;
the outcome, after 5.5 years of follow-up, was a lower rate of AF, a lower cardiovascular
mortality and a significant reduction in overall mortality in patients randomized to the AAI
modality. Subsequent publications of this same population showed a lower number of cases of
progression   to   heart   failure,   improved   echocardiographic   parameters24  and   fewer
thromboembolism events25. 
            In 1998, the results of the PASE (“Pacemaker Selection in the Elderly”) study were
published26. This study randomized 407 patients over 65 years of age and with bradycardia to
receive a DDDR versus VVIR pacemaker. After an average follow-up of 2.5 years, the quality of
life endpoint significantly improved in both groups (p<0.001) compared to the baseline situation,
but no significant differences were detected between the two groups except for a slight difference
in favor of using the DDDR pacemaker in patients with SND. No differences were found in
number of deaths, ACVA or admissions for heart failure. However, a lower incidence of AF in
the DDDR randomized group was demonstrated. The results of the study were partially clouded
because a very high rate of crossover (26%) from the VVIR to DDDR group was recorded due to
pacemaker syndrome during follow-up. This may have undervalued the benefit of DDDR pacing
in this type of patient.
            That same year, Mattioli published the results of a prospective study that analyzed the
incidence of atrial fibrillation as a function of the pacing modality27. It included 210 patients, 110
with SND and 100 with AV block, who received a physiologic PM (AAI, DDD, DDDR or VDD)
versus a ventricular PM (VVI or VVIR). Patients with a background of atrial fibrillation were
excluded, and the incidence of AF was 10% during the first year, 23% after 3 years and 31% after
5 years. The patients randomized to a physiologic PM had a lower risk of developing AF during
follow-up, and the greatest benefits were for patients with SND.
            The CTOPP (Canadian Trial of Physiologic Pacing)28 randomized 2568 patients with
pacemaker indication, 1474 to ventricular pacing (VVI or VVIR) and 1094 to physiologic pacing
(AAI, AAIR, DDD or DDDR). After an average follow-up of 3 years, no significant differences
were found in the combined endpoint of cardiovascular mortality and ACVA between both
groups. However, the annual incidence of atrial fibrillation was 5.3% in the physiologic pacing
group versus 6.6% in the ventricular pacing group. A relative risk reduction of 18% was
statistically significant (p=0.05). A subsequent analysis of this same study published in 2001 29
demonstrated that physiologic pacing was very beneficial for the patients most dependent on
pacemakers. Thus, those patients with an intrinsic cardiac frequency of less than 60 bpm during
the first follow-up had a lower rate of cardiovascular death or ACVA and a lower total mortality
(p<0.001).
            The MOST trial, published in 2002, randomizes 2010 patients with SND to receive a
VVIR versus DDDR pacemaker30. After completing an average follow-up of 2.7 years, the
primary endpoint of ACVA or total mortality occurred in 22.2% of the patients, and no
significant differences were observed between the two groups (p=0.32). However, a lower
incidence of AF was observed in the DDDR randomized group (p=0.008). The occurrence of
permanent AF was 26.7% in the VVIR group versus 15.2% in the DDDR group (p=0.001).
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            The preliminary findings of the UK-PACE trial31 were reported during the 2003 Congress
of the American College of Cardiology. This trial randomizes 2000 patients with AV block to a
DDDR versus VVIR pacemaker, and no differences are found in total or cardiac mortality
between the two groups.
               In all, almost 7000 patients have been included in randomized trials, and there is
indisputable proof of a lower incidence of atrial fibrillation and less progression to chronic AF
when a physiologic pacemaker is used in patients with permanent pacing indication.
Patients Without Associated Bradycardia
            In 1999, the results of PA3 32 were published. This study assesses the efficacy of atrial
pacing in patients with paroxysmal atrial fibrillation and without permanent pacing indication. In
order to be included, the patients had to have had at least three episodes of paroxysmal AF during
the preceding year in spite of having received correct antiarrhythmic treatment. A dual-chamber
pacemaker was implanted in 97 patients, and they were randomized to DDIR programming at 70
bpm or DDI at 30 bpm. The primary endpoint was the time up to the first recurrence of an atrial
tachycardia lasting more than 5 minutes. The counters of the device, which did not have
intracavity electrographs, were used for this purpose. This endpoint did not differ significantly in
the two groups.
    Subsequently, AV node ablation was performed in 67 patients, randomizing the DDDR PM at
70 bpm minimum frequency or VDD PM at 60 bpm33. There were also no differences detected in
the recurrence of AF in this second phase.
    This study has some methodological limitations, the main one being a high rate – 25% – of
group crossover from the DDI mode at 30 bpm to the DDIR mode at 70 bpm. In addition, the
DDIR programming only achieved 67% atrial pacing, and other studies have demonstrated that
the higher the percentage of pacing, the greater is the efficacy in preventing AF. Finally, the
primary endpoint is based on analysis of the PM counters, without electrographs that confirm the
recurrence of the arrhythmia. 
            In spite of all this, an analysis of the results of PA3  puts in doubt the efficacy of atrial
pacing in preventing episodes of AF in patients with associated bradycardia.
Pacing at Special Sites
A) Biatrial Pacing
            The association between disorders of intra- and inter-atrial conduction and the occurrence
of AF episodes has been known for some years34. Techniques of simultaneous pacing in both
atria35 have been proposed to correct this. This technique uses an electrode located inside the
coronary sinus and another in the right atrium; both are jointly connected to the atrial port by a
Y-connector. Some second-generation PMs have algorithms that resynchronize both atria in case
an event sensed in the opposite atrium occurs36.
            The French group directed by Dr. Daubert publishes the experience of a single center over
a period of 9 years37. It demonstrates a reduction of the P wave from 187 to 106 msec with
biatrial pacing. After an average follow-up of 34 months, a third of the patients is free of
arrhythmias, a third presents paroxysmal episodes but with maintenance of sinus rhythm, and the
remaining third has permanent atrial fibrillation.
            This technique has also been effectively used to prevent episodes of AF after heart
surgery38, 39,40. However, the technique is limited by the need for 2 electrodes, the high rate of
displacement of the coronary sinus electrode and the use of Y-connectors.
B) Dual-Site Right Atrial Pacing
            In this technique, an electrode is implanted in the right appendage and another in the
coronary sinus ostium. This succeeds in reducing the conduction time and achieves a more
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homogeneous atrial activation, thus eliminating the displacement problems of electrodes placed
inside the coronary sinus.
            Early publications19 demonstrated a beneficial effect of dual-site pacing versus single-site
pacing or no pacing. In a prospective randomized study that includes 118 patients, dual-site
pacing only demonstrates a tendency for longer times without arrhythmias. In the subgroup of
patients that continues under antiarrhythmic treatment, dual-site pacing from the right atrium
significantly reduces the number of atrial arrhythmia episodes.
C) Pacing at Special Sites
            The atrial pacing site is of utmost importance to the total conduction time. To try to
achieve the potential beneficial effects of dual-site pacing, different pacing sites in the right
atrium have been proposed, specifically Bachmann's bundle18 and the coronary sinus ostium42. In
a randomized study, Padeletti analyzes the effects of pacing in 46 patients with a history of AF.
During the pacing phase in the right appendage, the number of symptomatic AF episodes was
reduced from 6 to 2 a month, whereas with interatrial septum pacing the number was reduced
from 5 to 0.2 a month. In another study  44, septal pacing resulted in a subjective 68%
improvement of symptomatic episodes and an objective 60% reduction of the incidence of AF. 
              The results with Bachmann's bundle pacing are promising45. The electrode is easily
positioned by using a simple fluoroscopic reference, and this position is associated with a marked
reduction in the P wave duration. In a prospective study that included 120 patients, pacing from
Bachmann's bundle reduced the incidence of progression to permanent AF (45 versus 75%,
p<0.05) after an average follow-up of one year.
            In short, both techniques have proved to be somewhat useful, although in trials with short
follow-up periods and with a small number of patients. Of the two positions, Bachmann's bundle
offers the advantage of causing fewer problems in ventricular signal detection. The far field can
be significant in this group of patients; it limits the utility of mode exchange algorithms and
introduces incorrect information in the pacemaker event counters.
Prevention Algorithms
            Different atrial pacing algorithms have been developed, all designed for atrial overdrive
pacing and prevention of AF episodes. Basically they can be divided into four types46: atrial
overdrive pacing algorithms (Figure 1), response to atrial extrasystoles (to prevent short-long
sequences), response to sinus rhythm recovery, and post-exercise relative bradycardia sequence
prevention algorithms. The most commonly used algorithm is intended to stimulate the atrium
just above the sinus frequency to achieve unified atrial refractory periods. The higher the atrial
pacing percentage, the greater the effectiveness. However, excessively high frequencies are
perceived by the patient as a disagreeable sensation. Therefore, the objective is to achieve a high
percentage of atrial pacing without excessively increasing the patient's frequency.
            The efficacy of an atrial overdrive pacing algorithm has been analyzed in the ADOPT-A
trial47. A total of 288 patients with sinus node dysfunction and a background of paroxysmal or
persistent AF received a DDDR pacemaker with a lower frequency programmed at 70 bpm. In a
parallel design, the patients were randomized to activate or not activate the overdrive pacing
algorithm. After a 6-month follow-up, it was confirmed that activation of the algorithm caused an
increase in the pacing percentage of 92.9% versus 67.9% (p<0.001). The atrial fibrillation
percentage dropped 25% with the algorithm activated (2.5% vs 1.87%, p=0.005). The number of
rehospitalizations or the need for cardioversion did not differ between the two groups.
            The AFT (AF Therapy) Trial included 372 patients with paroxysmal AF, with or without
permanent pacing indication, in a complex protocol divided into 4 phases48. The first phase of
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Figure 1: Example of atrial overdrive pacing algorithms.  
DAO continuously monitors the atrial channel for intrinsic atrial events. When two P-waves are
sensed within 16 cardiac cycles, the atrial pacing rate is increased. The P waves do not need to be
consecutive. Following the delivery of the programmed number of DAO pacing cycles, pacing
cycle length is extended or increased to facilitate the search for intrinsic atrial activity. Once
atrial activity is sensed and meets the above criteria, the algorithm will automatically calculate
and provide an incremental A pacing rate just above the patients own circadian rhythm.
the study was a monitoring phase intended to obtain information on the way AF begins in this
population. The second phase compares the efficacy of conventional pacing. During the third
phase of the study, the efficacy of four combined pacing algorithms is analyzed and compared to
conventional DDDR pacing at 70 bpm. Unfortunately, it has only been possible to analyze data
from 97 patients because information was lost during follow-up and because of detection of
ventricular activity in the atrial channel. The prevention algorithms achieved a 34% reduction of
the AF rate (p<0.05). A subsequent subanalysis of this study49 showed how conventional pacing
was very effective in patients with AF and bradycardia, whereas the algorithms tended to be
more useful for those patients with prior AF and without bradycardia.
            The ASPECT trial (Atrial Septal Pacing Efficacy Clinical Trial) included 298 patients
who were randomized to receive the atrial electrode in the septum or another position in the right
atrium. After one month, those patients with recurrence of AF were randomized to conventional
pacing or algorithms activated during a 3-month phase. At the end of this phase, the PM of the
opposite   group   was   reprogrammed.   The   PM   counters   did   not   show   evidence   of   any
significantdifferences with activation of the algorithms, nor were any objective differences based
on the electrode position found, except that the symptomatic episodes were less frequent in those
patients who had an electrode implanted in the interatrial septum.
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 PREVENT Register
            Atrial fibrillation is a complex arrhythmia. Phase 1 of the AFT study48 demonstrated that
there are multiple mechanisms of AF initiation that differ in different patients. Nowadays,
modern PMs have numerous diagnostic functions that help to characterize the way AF begins in
a specific patient. In addition, the prevention algorithms generally vary, and it may be that not all
of them are beneficial in all patients. The prospective studies have a strict protocol that makes it
difficult to optimize programming for a specific patient. Therefore, to study the efficacy of the
AF prevention algorithms in the real world by using all the advantages of a PM in a particular
patient, we have designed the Prevent Register51.
            The Prevent-AF Register is prospective, non-randomized and multicentric. It includes
candidate patients for permanent pacing due to sinus node dysfunction (type I or IIa indication of
the AHA-ACC) 52 with or without prior paroxysmal atrial fibrillation. 
            Four preventive pacing algorithms are incorporated: Pace ConditioningTM, Post-PAC
ResponseTM, PAC SuppressionTM, Post-Exercise ResponseTM. The Pace Conditioning detects the
patient's   basal   frequency  and   increases   the   pacemaker   pacing  frequency  to   increase   the
percentage of paced beats, in an attempt to maintain patients slightly above their basal frequency.
The PAC Suppression is activated if atrial extrasystoles are detected, increasing the basal pacing
frequency in an attempt to suppress them. The Post-PAC Response prevents the compensatory
pause after an atrial extrasystole by eliminating the short-long sequences. The Post-Exercise Rate
Control prevents abrupt frequency drops after episodes of physical exercise. The Register was
implemented in 14 centers in Spain. A total of 68 patients (33 men, 35 women) were included
from April 2000 to April 2001. The average age was 72±12 years and the pacing indication was
sinus node dysfunction in all cases. A total of 53 patients (78%) had had documented paroxysmal
AF episodes prior to implant. 
            The recurrence of at least one episode of paroxysmal atrial fibrillation was documented in
a total of 32 patients during the monitoring phase, and at least one subsequent phase of
preventive   pacing   was   completed.   The   preventive   algorithms   were   programmed   on   an
individualized basis, based on information from the AF episode commencement mode. 
            The average atrial arrhythmic burden was reduced in the total group (32 patients) from
0.94 to 0.3 hours a day (Wilcoxon test: p=0.034) (Figure 2). In relative values, the average atrial
arrhythmic burden dropped from 3.9% to 1.3%, i.e. a 67% reduction. The mean atrial pacing
percentage rose from 72% to 78%, i.e. an increase of only 13%.
            The Register results confirm the usefulness of latest-generation pacemakers both for
diagnosing episodes of paroxysmal atrial fibrillation and for preventing them by means of pacing
algorithms. The diagnostic functions of the pacemaker provided relevant information on the
occurrence and development of atrial fibrillation in each patient. In this way, the most suitable
algorithms for preventing AF were programmed on an individualized basis. 
Atrial Tachycardia Termination Algorithms
            Many episodes of AF begin preceded by a rapid, relatively regular atrial tachycardia.
Some of these atrial tachycardias can be eliminated by overdrive pacing in a way similar to
overdrive pacing and termination of other tachycardias by reentry. To end atrial tachycardias,
algorithms similar to those used in implantable defribillators have been employed, and specific
algorithms have been designed to act in the atrium as 50 Hz bursts (Figure 3).
            These therapies have been tested in 537 patients possessing a DAI with atrial therapies53.
After an average follow-up of 11.4 months, the overall efficacy of the algorithms was 48%, with
59% in cases of atrial tachycardia and 30% in those cases classified as AF. The efficacy depends
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Figure 2. Change in AF Burden during follow up. Median AF burden reduced from 12% to 3%.
 
 
Figure 3: Overdrive pacing algorithms.
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on the arrhythmia cycle length, and it is lower the faster the atrial tachycardia. The main
limitation of this and similar work is that we know that many episodes of AF and atrial
tachycardia are self-limited and brief, and therefore the quantification of efficacy may be clearly
overestimated.
            In the ATTEST study54, the efficacy of atrial overdrive pacing in 368 patients possessing
a pacemaker was evaluated. The overdrive pacing algorithms terminated 54% of the episodes,
although the reduced percentage of atrial arrhythmias was not statistically significant: from 42
hours a month to 1.3 hours a month (p=0.2).
Conclusions
            As we have seen in this review of the state-of-the-art, several parallel lines of research
have been developed in recent years to treat patients with AF, either associated or not with
bradycardia. The situation may seem confusing, and even more so if we consider some
limitations of this work.
            The first limitation is that in each study, we are analyzing something different that has not
been studied previously. The data that we have from classical prevalence studies1,2,3 are based on
records, either with ECG or by Holter, of AF episodes, most of them symptomatic. In most of the
mentioned studies, the presence or absence of AF is analyzed according to records of the
pacemaker itself. This has two limitations. The first is that, as the devices and detection criteria
are different, the data from a study may not be comparable to data from other studies. The second
is that, as most AF episodes are asymptomatic, we are overestimating the incidence and it is not
easy to extrapolate the data from these studies, which use symptomatic episodes as diagnostic or
efficacy criteria.
            Another limitation is that atrial fibrillation is a complex, dynamic arrhythmia. For reasons
of protocol, the programming of devices in most of the trials has been based on a rigid, inflexible
protocol. 55. Perhaps if there had been a little more freedom on adapting the algorithms to each
patient, the degree of efficacy of the algorithms would have been higher. In addition, we are
increasingly more aware of the adverse effect of VD apex pacing on the hemodynamics of these
patients55. This effect at least partially explains the high incidence of atrial arrhythmias in
patients with a permanent PM that was not accounted for in some studies. Perhaps in the future,
with new algorithms tending to reduce VD pacing to the necessary minimum and with the
expansion of resynchronization techniques, the approaches for treating atrial arrhythmias may
yield greater benefits.
            Finally, the follow-up of these studies has been very short. In Andersen's classical study8,
the AAI pacemaker did not yield benefits until after 5 years of follow-up; however, the data we
have on these new techniques are limited to 6-month or one-year follow-ups. We need a longer
follow-up to be able to accurately evaluate the efficacy of these devices.
            From the data presented to date, we can conclude that the benefits obtained by implanting
two electrodes, either in the right atrium or in both atria, are insignificant and probably do not
justify the increased complexity of the implant. These techniques should be limited to research
protocols, to try to identify the type of patient that would benefit the most.
            The prevention algorithms are sound and barely raise the PM price, although their utility
is limited. Nowadays, they could be used for different categories of patients:
1)Patients with PM indication and documented AF episodes.
2)Patients with a background of AF who develop secondary symptomatic bradycardia to
medication.
3)Patients with paroxysmal atrial arrhythmias not suppressible by ablation and drug-refractory
techniques for whom AV node ablation is considered as a therapeutic measure.
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             For the time being, the results of pacing do not justify its therapeutic use in patients with
atrial fibrillation or atrial arrhythmias without associated bradycardia. One unanswered question
is the optimum site of atrial pacing. Current data suggest a rather inconsistent benefit with septal
pacing, whether it be from the coronary sinus ostium or Bachmann's bundle. But we still have
very few data. Trials with more patients and longer follow-up periods are needed to change the
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